表紙
市場調查報告書

糖尿病管理:胰島素幫浦市場

Diabetes Management: Insulin Pumps Market (2019)

出版商 Datamonitor Healthcare 商品編碼 858333
出版日期 內容資訊 英文 116 Pages
商品交期: 最快1-2個工作天內
價格
糖尿病管理:胰島素幫浦市場 Diabetes Management: Insulin Pumps Market (2019)
出版日期: 2019年09月30日內容資訊: 英文 116 Pages
簡介

本報告提供全球胰島素幫浦市場相關調查,糖尿病概要,胰島素幫浦、新型的人工胰臟系統相關分析,市場預測,及競爭情形分析等彙整資料。

摘要整理

第1章 糖尿病概要

  • 盛行率
  • 糖尿病定義
    • 症狀
    • 併發症
    • 診斷、治療
    • 糖尿病的成本
  • 參考資料

第2章 自動胰島素幫浦

  • 胰島素幫浦
    • Insulet Corporation
    • Medtronic
    • Roche
    • Tandem Diabetes Care
    • Valeritas
  • 新的人工胰臟系統
    • Beta Bionics
    • Bigfoot Biomedical
    • Cellnovo/TypeZero
    • Dexcom/TypeZero and Tandem Diabetes Care
    • Diabeloop
    • Senseonics/Roche/TypeZero
  • 參考資料

第3章 市場分析

  • 胰島素幫浦市場
    • 市場預測:世界
    • 市場成長的推動要素、阻礙因素
    • 市場預測:各地區
    • 美國市場
    • EU主要5個國家
    • 日本市場
    • 其他的市場
  • 競爭分析
    • 市場佔有率:世界
    • 市場佔有率:地區
  • 參考資料

附錄A:企業清單

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: #MDT19015

Drug Overview:

Valued at nearly $3bn in 2018, the Global Insulin Pumps Market is growing at a fast pace-at a compound annual growth rate (CAGR) of approximately 12%-reaching more than $5bn by 2023.

The market is being driven by strong demand, increasing awareness and adoption of next-generation hybrid closed-loop systems, solid clinical outcomes, and good reimbursement. Market penetration is low, leaving much room for growth.

According to the International Diabetes Federation (IDF), approximately 425 million adults (20-79 years of age) have diabetes worldwide, and this number is expected to rise nearly 50% to approximately 629 million by 2045. More than 1.25 million people have type 1 diabetes in the US alone.

There is a strong need for automated continuous insulin delivery as a replacement for cumbersome multiple daily (insulin) injections ("MDI") using painful pens/needles, which are prone to user error and may leave many type 1 (and insulin-requiring type 2) patients at risk for dangerous complications.

Overall, the insulin pumps market is an evolving market driven by innovation. While Medtronic clearly dominates, technological advances are spurring intense competition. There is a rush to develop even smarter automated hybrid closed-loop systems (artificial pancreas or "AP" systems) driven by "machine learning" or artificial-intelligence-based algorithms. These systems lessen patient burden and autonomously adapt to individuals' glycemic needs and lifestyles to significantly improve blood glucose control and quality of life for millions of diabetes patients worldwide.

This comprehensive medical market and technology report provides:

  • prevalence of diabetes
  • insulin pump portfolios, key product features, and technical limitations
  • product pipelines
  • emerging startups/technologies
  • key trends and opportunities
  • market drivers and limiters
  • market and competitive analysis-including 5-year global and regional market forecasts, global/regional market share (2018), company overview, financials, and strategic growth strategies.

Markets covered by this analysis include: the US, Japan, the five major EU markets (France, Germany, Italy, Spain, and the UK), and the Rest of World (RoW) markets, which includes all other countries. Market forecasts are for the 2018-23 time period.

Table of Contents

Executive Summary

  • i. Diabetes overview
  • ii. Automated insulin pump technology
  • iii. Insulin pumps market
  • iv. Competition
  • v. Methodology
  • vi. Bibliography
  • Exhibit-1: Insulin pumps, global market forecast ($m), 2018-23

1. Diabetes Overview

  • 1.1. Prevalence
  • 1.2. Diabetes defined
    • 1.2.1. Symptoms
    • 1.2.2. Complications
    • 1.2.3. Diagnosis and treatment
    • 1.2.4. Cost of diabetes
  • 1.3. Bibliography

2. Automated Insulin Pumps

  • 2.1. Insulin pumps
    • 2.1.1. Insulet Corporation
    • 2.1.2. Medtronic
    • 2.1.3. Roche
    • 2.1.4. Tandem Diabetes Care
    • 2.1.5. Valeritas
  • 2.2. Emerging artificial pancreas systems
    • 2.2.1. Beta Bionics
    • 2.2.2. Bigfoot Biomedical
    • 2.2.3. Cellnovo
    • 2.2.4. Diabeloop
    • 2.2.5. EOFlow
    • 2.2.6. Ypsomed
  • 2.3. Bibliography
  • Exhibit 2-1: Leading automated insulin pump brands, by manufacturer
  • Exhibit 2-2: Selected leading automated insulin pumps and hybrid closed-loop ("artificial pancreas") systems
  • Exhibit 2-3: The three-step Omnipod insulin delivery process
  • Exhibit 2-4: The new Omnipod DASH
  • Exhibit 2-5: The MiniMed 670G hybrid closed-loop insulin pump
  • Exhibit 2-6: The Tidepool Loop app for iPhone and Apple Watch
  • Exhibit 2-7: The new t:slim X2 insulin pump with Basal-IQ technology
  • Exhibit 2-8: The V-Go 24-hour wearable insulin delivery device for type 2 diabetes
  • Exhibit 2-9: Selected companies/startups developing artificial pancreas systems
  • Exhibit 2-10: Selected artificial pancreas systems under development
  • Exhibit 2-11: The iLet bionic pancreas system
  • Exhibit 2-12: The Bigfoot Loop artificial pancreas system
  • Exhibit 2-13: The Cellnovo Gen 3 mobile-based insulin delivery system
  • Exhibit 2-14: The Diabeloop DBLG1 hybrid closed-loop system
  • Exhibit 2-15: The mylife YpsoPump system

3. Market Analysis

  • 3.1. Insulin pumps market
    • 3.1.1. Market forecast: global
    • 3.1.2. Market drivers and limiters
    • 3.1.3. Market forecast: by region
    • 3.1.4. US market
    • 3.1.5. Five major EU markets
    • 3.1.6. Japanese market
    • 3.1.7. Rest of the world market
  • 3.2. Competitive analysis
    • 3.2.1. Market share: global
    • 3.2.2. Market share by region
  • 3.3. Financials and corporate growth strategies
    • 3.3.1. Insulet Corporation
    • 3.3.2. Animas/Johnson & Johnson
    • 3.3.3. Medtronic
    • 3.3.4. Roche
    • 3.3.5. Tandem Diabetes Care
    • 3.3.6. Valeritas
  • 3.4. Bibliography
  • Exhibit 3-1: Insulin pumps, global market forecast ($m), 2018-23
  • Exhibit 3-2: Insulin pumps market, forecast sales by region ($m), 2018-23
  • Exhibit 3-3: Insulin pumps market, global share by supplier, 2018
  • Exhibit 3-4: Insulin pumps market, estimated share by supplier and region, 2018
  • Exhibit 3-5: Insulet, revenues by segment, FY2018
  • Exhibit 3-6: Medtronic, revenues by segment, FY2019
  • Exhibit 3-7: Roche, revenues by segment, FY2018
  • Exhibit 3-8: Tandem Diabetes Care, revenues by segment, FY2018
  • Appendix A: company listing